Effect of H. Pylori Eradication on the Fate of H. Pylori-associated Gastric Polyp

• Status: Completed
• Trial end date: 2019-04-30
• Target enrollment: 0
• Participant gender: All

Summary

Evaluation of the effect of H. pylori eradication on regression of H. pylori-related gastric polyp (Ranomized controlled trial)

1. Study design: open labeled RCT

2. Study group H. pylori eradication group (N=17), non-eradication group (N=15)

3. Treatment plan

1. Baseline EGD

: 0.3-1cm sized polyp - bx & CLO test (antrum & body)

==> if H. pylori positive and eligible patients, randomization

2. Triple therapy

3. UBT (4week after eradication)

4. Follow-up EGD: gross finding, CLO test

4. Evaluation of polyp regression

1. disappear

2. regression over 50% (size, number)

3. no change or increase (size, number)

• Phase: Phase 4
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Kyungpook National University; Kyungpook National University Hospital
• Treatments: Clarithromycin

Criteria

Inclusion Criteria:

• Gastric polyp with current infection of H. pylori

• Gastric polyp size with 3mm-10mm

• Age of 20 yr - 70yr

Exclusion Criteria:

• Gastric ulcer ir duodenal ulcer (healing stage or acute stage)

• Use of PPI within 4weeks

• Liver cirrhosis, renal insufficiency, other serious chronic or acute disease

• Current infection of other bacteria, virus, or fungus

• Any cancer, psychologic disease

• Heavy drinker

• Drug abuser

• Pregnant women

• Penicillin allergy

• Use of digoxin, antifungal, wafarin

• Previous H. pylori eradication

• Gastric polyp with bleeding or malignant transformation

• Tiny polyp less than 3mm.